Скачать или смотреть Issues in allogeneic HSCT: Therapeutic options for post-transplant relapse

Prof David Marks talks to ecancer at the European School of Haematology (ESH) meeting: International Conference on Acute Lymphoblastic Leukaemia about the main problems clinicians and patients face after a haematopoietic stem cell transplant (HSCT) is given and the options available to treat this.

Prof Marks reviews data about the therapeutic options available in the post-relapse setting - which includes administering a second transplant and CAR T-cell therapy.

He also describes the risk factors that are associated with an increased risk of relapse in these patients and the role of maintenance therapy to reduce this risk.

Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.